SISTEMAS GENÓMICOS
A MEMBER OF SYNLAB

NIPT

Agile-NIPT for MGI®

Sistemas Genómicos presents **Agile-NIPT for MGI®, the most complete MGI sequencing platform test available for noninvasive prenatal screening for chromosomal aneuploidies** present in the fetus, as well as establishing gender.

THE MOST COMPLETE SOLUTION ON THE MARKET

Agile-NIPT for MGI® is **CE-IVD marked** and contains **reagents** to process 48 samples with the corresponding bioinformatics analysis, visualization and personalized report by the **GeneSystems© platform.**

The work process involves a "hands-out" manipulation time, completed in 3 hours, once the circulating free DNA *(cfDNA)* has been obtained. This process can be fully automated.

Validated complete bioinformatic analysis.

Simple and immediate generation of individualized reports.

Integration in user's facilities.

ABOUT US

Sistemas Genómicos is a pioneering company in the application of Next Generation Sequencing technology for genetic diagnosis and has extensive experience in Prenatal Diagnosis through applying different techniques specially developed for amniotic fluid samples, chorionic villus sampling and cordocentesis.

Accredited and certified by the major entities in quality assurance (ISO9001, ISO13485, ISO17025, and ISO15189), we offer solutions to accelerate and standardize clinical genetic testing enabling clinicians to provide accurate diagnostics to their patients.

OUR MISSION

We strive to provide the best **diagnostic solutions** with the best technology available to maximize patient benefit.

Our kits for noninvasive prenatal screening allow the implementation of this service in hospitals and other centers' facilities without externalizing any sample, with highly reliable results, reducing times for obtaining the report.

Agile-NIPT for MGI® kit
library preparation

Full automation possible

Sample sequencing on **MGI** platforms

Analysis and data interpretation on **GeneSystems©**

Agile-NIPT for MGI®

Agile-NIPT for MGI® is an integrated solution that includes bioinformatics analysis, visualization and personalized report by **GeneSystems©** platform.

This system, optimized and friendly-use, allows a **fast implementation in lab routines**, without needs of extra resources to maximize the number of processed samples.

Agile-NIPT for MGI® allows detection of chromosomal abnormalities in the fetus at an early stage of the pregnancy, as well as the gender of the fetus using a sample of maternal blood. It **examines all the chromosomes.**

Agile-NIPT for MGI® identifies microdeletions related to 10 important genetic syndromes.

- **Trisomy 21 associated with Down's syndrome**
- **Trisomy 18 associated with Edwards' syndrome**
- **Trisomy 13, associated with Patau syndrome**
- **Sex chromosome aneuploidies:**
  - Turner syndrome (45, X0)
  - Klinefelter syndrome (47, XXY)
  - Triple X syndrome (47, XXX)
  - Jacobs syndrome (47, XYY)
  - Polisomy X
- **Microdeletions and determined microduplications***
- **Mosaicisms (according to cfDNA)**

SYNDROME	CHROMOSOMAL REGION SIZE	INCIDENCE	CAUSED BY MICRODELETION
Angelman Syndrome (15q11.2-q13)	5-7 Mb	1/ 12000-20000	65-75% cases
Prader Willy Syndrome (15q11.2-q13)	4-6 Mb	1/ 10000-30000	65-75% cases
1p36 deletion Syndrome	1.5-10 Mb	1/ 5000 -10000	-
Crit-du-chat Syndrome (5p)	0.560-40 Mb	1/15000 - 50000	-
Wolf-Hirschhorn (4p16.3)	0.5-30 Mb	1/ 50000	-
Jacobsen Syndrome (11q23-qter)	5-20 Mb	1/ 100000	-
Langer-Giedion Syndrome (8q24.1)	2.8-14 Mb	‹1 / 1000000	-
Di George II Syndrome (10p14-p13)	4.19- 12.072 Mb	1/ 200000	-
16p11.2-p12.2 deletion	7.1-8.7 Mb	-	-
Phelan-McDermind Syndrome (22q13.3)	0.1-9Mb	1/8000-15000*	80% cases

* www.pmsf.org/what_is_pms/

The algorithm of detection associates each chromosome to a low, high or undetermined risk depending on the obtained signal:

LOW RISK
Very low probability of fetal chromosomal aneuploidy in any of the analysed chromosomes.

HIGH RISK
High probability of fetal chromosomal aneuploidy in the indicated chromosome. The result should be confirmed by performing a definitive diagnostic test such as invasive prenatal chorionic villus sampling or amniotic fluid testing.

UNDETERMINED RISK
The risk of aneuploidy in the indicated chromosome cannot be determined by the values obtained from the test, because although the result may not be normal, it is not sufficiently abnormal to be high risk.

Agile-NIPT for MGI® has a high precision, supported by strict validation processes. Its combination with other prenatal studies (fetal ultrasound or biochemical screening performed in the first trimester), **allows the reduction of false positives to less than 0.1%.**

The result is a **drastic decrease in unnecessary invasive tests,** with a significant benefit for pregnant women and the health system itself.

Agile-NIPT for MGI® can be performed **from week 9 of pregnancy** (with a minimum fetal fraction of 3.5%). It is particularly indicated in women who want to rule out chromosomal aneuploidies regardless of their genetic condition or family history, it can be used for all pregnant women, including pregnancies achieved through assisted reproductive techniques and oocyte donation and twins genetically identical, or twins not genetically identical if fetal fraction is suitable for the test allowing aneuploidies detection in both fetus.

DESIGN AND PROTOCOL

The working protocol is optimized to make the libraries in 3 simple steps and in the same tube, reducing the risk of errors during the process:

1 **Sample preparation:** repair of cfDNA.

2 **Library synthesis.**

3 **Library amplification:** obtaining a large number of copies of DNA fragments by PCR introducing the compatible index with NGS of MGI that also allows sequencing of multiple samples by run or lane.

DNA repair   Library synthesis   Index and amplification   Sequencing   GeneSystems© Platform

This technology allows to generate libraries with a high capacity of multiplexing and low ranges of duplication providing the following advantages:

- It performs from only 5ng of double-stranded cfDNA, obtained from maternal plasma without need of fragmentation.
- Higher perfomance compared to other technologies.
- Fast and simple process.
- Uniform coverage regardless of content in GC.
- The required materials are commonly used in the laboratory.

SENSITIVITY AND SPECIFICITY

To obtain the values of sensitivity and specificity, the samples were treated following the preanalytical recommendations for obtaining DNA. The libraries were processed with **Agile-NIPT for MGI®** and sequenced on MGI's NGS platforms. Finally, we proceeded to the analysis of the reads obtained by an informatic algorithm, developed entirely by Sistemas Genómicos and validated by independent centers.

CONDITION	VN	FN	VP	FP	SPECIFICITY	SENSITIVITY	VPP	VPN
Trisomy 21	13572	0	77	1	›99.9%	›99.9%	›98%	›99.9%
Trisomy 18	13705	0	14	3	›99.9%	›99.9%	›82%	›99.9%
Trisomy 13	13731	0	5	2	›99.9%	›99.9%	›71%	›99.9%
Trisomies 9, 16, 22	13741	0	0	0	›99.9%	-	-	›99.9%
Aneuploidies of sexual chromosomes (XO, XXY, XXX, XYY)	13717	0	6	0	›99.9%	›99%	›99%	›99.9%

CONDITION	SENSITIVITY
Fetal gender	›99.9%

GeneSystems©

SISTEMAS GENÓMICOS

GeneSystems© hosts a number of **versatile and easy-to-use tools for analyzing data from massive sequencing, visualization and interpretation of results**. It offers a complete and personalized service, adaptable to needs.

This platform, developed entirely in a cloud computing envirnoment with advanced bioinformatic algorithms of Sistemas Genómicos, allows high availability and scalability of data, minimizing the consumption of the user's own resources.

The platform is adapted to solve the needs during the analysis process, from the analysis of the results from sequencing to the preparation of the final report. Its intuitive and optimized interface for the data generated from the sequencing of the libraries processed with **Agile-NIPT for MGI®** is designed to be **managed without bioinformatics knowledge.**

Within hours, **GeneSystems©** is able to analyze the data of **Agile-NIPT for MGI®** and to detect aneuploidies in any fetal chromosome. After low coverage sequencing of the complete genome (0.1%). **GeneSystems©** aligns the sequencing data of the samples against the reference genome. Using an algorithm developed and validated by Sistemas Genómicos, **the platform detects alterations in the chromosomes**, based on variations in the counting of segments of the fetal chromosomes, as opposed to a normalization of control samples.

For Sistemas Genómicos customer is at the center of our work. This includes a **personalized service** to enable a seamless implementation of diagnostic next generation sequencing**.**

We offer personalised training programs to ensure a quick acquisition of the skill set required to successfully and reliably harness the latest advances in sequencing technology to maximize patient benefit.

GeneSGKit®

Certifications

The manufacturing of the kits and bioinformatics analysis is certified by **ISO13485** and **CE-IVD marked.**

References

Agile-NIPT for MGI® 48 reactions Ref.: LV4615 (Kit CE-IVD)

SISTEMAS GENÓMICOS

atención-cliente@sistemasgenomicos.com
www.sistemasgenomicos.com

Parque Tecnológico de Valencia - Ronda G. Marconi, 6
46980 Paterna, Valencia (Spain)

Tel. +34 961 366 150
Fax +34 961 366 151